Trending

Roivant

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could

X

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

https://pharmaphorum.com/news/phase-3-wins-put-dermavant-closer-to-filing-otezla-rival-tapinarof/

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with

X

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

https://pharmaphorum.com/news/roche-begins-phase-3-trial-of-actemra-in-covid-19-pneumonia/

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

A new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant

X

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

https://pharmaphorum.com/news/sumitomo-roivant-close-3-billion-deal-forming-sumitovant/

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

Six weeks after Sumitomo Dainippon Pharma agreed a $3 billion deal to license a host of drug candidates

X

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

https://pharmaphorum.com/news/sumitomo-and-roivant-put-flesh-on-bones-of-3bn-rd-deal/

Sumitomo Dainippon bolts on pipeline via $3bn Roivant alliance

Sumitomo Dainippon bolts on pipeline via $3bn Roivant alliance

Vivek Ramaswamy’s Roivant group has forged its biggest and most wide-ranging alliance to date, licensing dozens of drugs

X

Sumitomo Dainippon bolts on pipeline via $3bn Roivant alliance

https://pharmaphorum.com/news/sumitomo-dainippon-bolts-on-pipeline-via-3bn-roivant-alliance/

Roivant wins $200m backing to expand R&D operations

Roivant wins $200m backing to expand R&D operations

Biotech startup Roivant has won a further $200 million backing from investors in a financing round valuing the

X

Roivant wins $200m backing to expand R&D operations

https://pharmaphorum.com/news/roivant-wins-200m-backing-to-expand-rd-operations/

Ramaswamy’s Roivant signs diabetes drug deal with Poxel

Ramaswamy’s Roivant signs diabetes drug deal with Poxel

Biotech entrepreneur hopes to bounce back from Alzheimer’s disappointment

X

Ramaswamy’s Roivant signs diabetes drug deal with Poxel

https://pharmaphorum.com/news/ramaswamys-roivant-signs-diabetes-drug-deal-poxel/

Axovant CEO David Hung quits after Alzheimer’s drug failure

Axovant CEO David Hung quits after Alzheimer’s drug failure

Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.

X

Axovant CEO David Hung quits after Alzheimer’s drug failure

https://pharmaphorum.com/news/axovant-ceo-hung-quits-alzheimers-drug-failure/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com